WO1997031633A1 - Methods of treating or preventing sleep apnea - Google Patents
Methods of treating or preventing sleep apneaInfo
- Publication number
- WO1997031633A1 WO1997031633A1 PCT/US1997/003028 US9703028W WO9731633A1 WO 1997031633 A1 WO1997031633 A1 WO 1997031633A1 US 9703028 W US9703028 W US 9703028W WO 9731633 A1 WO9731633 A1 WO 9731633A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperidin
- added
- mol
- mixture
- indol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Definitions
- Tachykinins are a family of peptides which share a common amidated carboxy terminal sequence.
- Substance P was the first peptide of this family to be isolated, although its purification and the determination of its primary sequence did not occur until the early
- neurokinin A also known as substance K, neuromedin L, and neurokinin ⁇
- neurokinin B also known as neuromedin K and neurokinin ⁇
- Tachykinins are widely distributed in both the central and peripheral nervous systems, are released from nerves, and exert a variety of biological actions, which, in most cases, depend upon activation of specific receptors expressed on the membrane of target cells. Tachykinins are also produced by a number of non-neural tissues.
- the mammalian tachykinins substance P, neurokinin A, and neurokinin B act through three major receptor subtypes, denoted as
- NK-1, NK-2, and NK-3 are present in a variety of organs.
- Substance P is believed inter alia to be involved in the neuro transmission of pain sensations, including the pain associated with migraine headaches and with arthritis. These peptides have also been implicated in gastrointestinal disorders and diseases of the gastrointestinal tract such as inflammatory bowel disease. Tachykinins have also been implicated as playing a role in numerous other maladies, as discussed infra. Tachykinins play a major role in mediating the sensation and transmission of pain or nociception, especially migraine headaches, see, e.g.. S.L. Shepheard, et al.. British Journal of Pharmacc-lQgy, 108:11-20 (1993); S.M. Moussaoui, et al render European Journal of Pharmacology.
- tachykinin receptor antagonists wiD serve to control these clinical conditions.
- the earliest tachykinin receptor antagonists were peptide derivatives. These antagonists proved to be of limited pharmaceutical utility because of their metabolic instability.
- Sleep apnea is a condition in which apnea coours during sleep without subjective symptom. It is more prevailing in male middle- and old-aged persons in their forties and fifties. Approximately one per 100 persons is reported to suffer from this condition. In sleep apena there is repeated many times in sleep a sequence of 20-40 seconds apnea, about 10-20 seconds pneusis, and 20-40 seconds apnea. For example, during a 6.5 hour sleep, approximately 400 occurrences of apnea may occur.
- sleep apnea there occur phenomena, such as daytime sleepiness, loss of energy or appetite, swelling in the lower part of the body, and shortness of breath. Increase in leukocyte number, development of polycythemia, and even cardiomegaly are associated with severe instances of sleep apnea. Sleep apnea is observed not only in adults of middle or advanced age, but also in infants, and may be an indirect cause of hypertension, cardiac insufficiency, and arrh * ythmia, possibly being a leading cause of sudden infant death syndrome.
- SIDS Sudden Infant Death Syndrome
- R 1 and R 2 are independently selected from the group consisting of hydrogen, methyl, methoxy, chloro, and trifluoromethyl, with the proviso that no more than one of R 1 and R 2 can be hydrogen;
- R a , R D , and R c are independently selected from the group consisting of hydrogen and Ci-C ⁇ alkyl;
- Ci-C ⁇ alkyl refers to straight or branched, monovalent, saturated aliphatic chains of 1 to 6 carbon atoms and includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, and hexyl.
- the term "Ci-C ⁇ alkyl” includes within its definition the term “C 1 -C3 alkyl”.
- Halo represents chloro, fluoro, bromo or iodo.
- haloformate refers to an ester of a haloformic acid, this compound having the formula
- X is halo
- Rd is Ci-C ⁇ alkyl.
- Preferred haloformates are bromoformates and chloroformates. Especially preferred are chloroformates. Those haloformates wherein R d is C 3 -C 6 alkyl are especially preferred. Most preferred is isobutylchloroformate.
- the compounds prepared in the processes of the present invention have an asymmetric center.
- the compounds produced in the present invention may occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. Processes for preparing such asymmetric forms, individual isomers and combinations thereof, are within the scope of the present invention.
- the terms "R” and “S” are used herein as commonly used in organic chemistry to denote specific configuration of a chiral center.
- the term “R” (red us) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group.
- S sinister
- S refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group.
- the priority of groups is based upon their atomic number (in order of decreasing atomic number).
- a partial list of priorities and a discussion of stereochemistry is contained in NOMENCLATURE OF ORGANIC COMPOUNDS: PRINCIPLES AND PRACTICE, (J.H. Fletcher, et al. eds., 1974) at pages 103-120.
- the older D-L system is also used in this document to denote absolute configuration, especially with reference to amino acids.
- a Fischer projection formula is oriented so that the number 1 carbon of the main chain is at the top.
- the prefix "D” is used to represent the absolute configuration of the isomer in which the functional (determining) group is on the right side of the carbon atom at the chiral center and "L", that of the isomer in which it is on the left.
- Patent Cooperation Treaty Publication WO 95/14017 published May 26, 1995, teaches, inter alia, a series of tachykinin receptor antagonists of Formula II
- n are independently 0-6;
- Z is -(CHR 4 )p-(CHR6) Q -, where,
- p is 0 or 1
- q is 0 or 1
- R 4 and R 6 are independently selected from the group consisting of hydrogen and C 1 -C 3 alkyl
- R a , R b , and R c are independently selected from the group consisting of hydrogen and Ci-C ⁇ alkyl;
- R 1 and R 2 are independently hydrogen, halo, Ci-C ⁇ alkoxy, Ci-C ⁇ alkylthio, nitro, trifluoromethyl, or Ci- C 6 alkyl;
- Particularly preferred compounds are those of Formula II in which m and n are both 1; R 1 and R 2 are independently hydrogen, methoxy, ethoxy, chloro, fluoro, trifluoromethyl, methyl, and ethyl; Z is methylene; and Y, when combined with the heterocyclic group to which it is attached, forms 4-(piperidin- 1-yl )piperidin- 1-yl, 4- (cyclohexyl)piperazdn-l-yl, 4-(phenyl)piperazin-l-yl, or 4- (phenyl)piperi din- 1-yl.
- Chlorotrimethylsilane (70.0 ml, 0.527 mol) was added at a moderate rate to a stirred slurry of D-tryptophan (100.0 g, 0.490 mol) in anhydrous methylene chloride (800 ml) under a nitrogen atmosphere. This mixture was continuously stirred for 4.25 hours. Triethylamine (147.0 ml, 1.055 mol) was added, followed by the addition of a solution of triphenylmethyl chloride (147.0 g, 0.552 mol) in methylene chloride (400 ml) using an addition funnel. The mixture was stirred at room temperature, under a nitrogen atmosphere for at least 20 hours. The reaction was quenched by the addition of methanol (500 ml).
- the solution was concentrated on a rotary evaporator to near dryness and the mixture was redissolved in methylene chloride and ethyl acetate. An aqueous work-up involving a 5% citric arid solution (2X) and brine (2X) was then performed. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness on a rotary evaporator. The solid was dissolved in hot diethyl ether followed by the addition of hexanes to promote crystallization.
- the mixture was allowed to warm to room temperature under a nitrogen atmosphere for at least 20 hours.
- the mixture was concentrated on a rotary evaporator and then redis solved in methylene chloride and an aqueous work-up of 5% citric acid solution (2X), saturated sodium bicarbonate solution (2X), and brine (2X) was performed.
- the organic layer was dried over anhydrous sodium sulfate and concentrated to dryness on a rotary evaporator.
- the desired product was then recrystallized from hot ethyl acetate to yield 215.8 g (0.381 mol, 95%) of analytically pure material.
- RED-AL® [a 3.4 M, solution of sodium bis(2- methoxyethoxy)aluminum hydride in toluene] (535 ml, 1.819 mol), dissolved in anhydrous tetrahydrofuran (400 ml) was slowly added using an addition funnel to a refluxing solution of the acylation product, (R)-3- (lH-indol-3-yl)-N-(2-methoxybenzyl)-2-(N- triphenylmethylamino)propanamide (228.6 g, 0.404 mols) produced supra, in anhydrous tetrahydrofuran (1.0 L) under a nitrogen atmosphere. The reaction mixture became a purple solution.
- the reaction was quenched after at least 20 hours by the slow addition of excess saturated Rochelle's salt solution (potassium sodium tartrate tetrahydrate).
- the organic layer was isolated, washed with brine (2X), dried over anhydrous sodium sulfate, filtered, and concentrated to an oil on a rotary evaporator. No further purification was done and the product was used directly in the next step.
- Cyclohexylpiperazine (10.0 g, 0.059 mol) was added to ten volumes of methylene chloride at room temperature. To this mixture was added sodium hydroxide (36 ml of a 2N solution, 0.072 mol) and tetrabutylammonium bromide (1.3 g, 0.004 mol). After the addition of the sodium hydroxide and tetrabutylammonium bromide, methyl bromoacetate (7.0 ml, 0.073 mol) was added and the reaction, mixture was stirred for four to six hours. The progress of the reaction was monitored by gas chromatography. .
- the organic fraction was separated and the aqueous phase was back-extracted with methylene chloride.
- the organic phases were combined and washed twice with deionized water, once with saturated sodium bicarbonate solution, and then with brine.
- the organic phase was dried over magnesium sulfate and the solvents were removed in vacuo to yield methyl 2-((4-cyclohexyl)piperazin-l-yl)acetate as a yellowish oil.
- the title compound was prepared by dissolving the methyl 2-((4-cyclohexyl)piperazin-l-yl)acetate (10.0 g, 0.042 mol) in ten volumes of diethyl ether. This solution was cooled to 15°C and then potassium trimethylsilanoate (5.9 g, 0.044) was added. This mixture was then stirred for four to six hours. The reaction product was removed by filtration, washed twice with five volumes of diethyl ether, then washed twice with five volumes of hexanes, and then dried in a vacuum oven for 12-24 hours at 50°C.
- the title compound was prepared by first cooling 2-((4- cyclohexyl)piperazin-l-yl)acetic acid potassium salt to a temperature between -8°C and -15°C in 5 volumes of anhydrous methylene chloride. To this mixture was added isobutylchloroformate at a rate such that the temperature did not exceed -8°C. The resulting reaction mixture was stirred for about 1 hour, the temperature being maintained between -8°C and -15°C.
- the reaction was quenched by the addition of 5 volumes of water.
- the organic layer was washed once with a saturated sodium bicarbonate solution.
- the organic phase was then dried over anhydrous potassium carbonate and filtered to remove the drying agent.
- To the filtrate was then added 2 equivalents of concentrated hydrochloric acid, followed by 1 volume of isopropyl alcohol.
- the methylene chloride was then exchanged with isopropyl alcohol under vacuum by distillation.
- the final volume of isopropyl alcohol was then concentrated to three volumes by vacuum.
- the reaction mixture was cooled to 20 °C to 25°C and the product was allowed to crystallize for at least one hour.
- the desired product was then recovered by filtration and washed with sufficient isopropyl alcohol to give a colorless filtrate.
- the crystal cake was then dried under vacuum at 50°C. MS 560 (M+l + ).
- Deionized water (1.2 L) was then added to the mixture and the layers separated. The aqueous layer was back-extracted with methylene chloride (2.4 L). The organic fractions were combined and washed with deionized water (3 x 1.2 L), a saturated sodium bicarbonate solution (1.1 L) and a saturated sodium chloride solution (1.1 L). The organic fraction was then dried over anhydrous magnesium sulfate and concentrated to an oil on a rotary evaporator to -yield 1.613 kg (93.5%) of methyl 2-(4-(piperidin-l-yl)piperidin-l-yl)acetate.
- the title compound was. prepared by first admixing (R)-2- amino-3-(lH-indol-3-yl)-l-[N-(2-methoxybenzyl)acetylamino]propane dihydrochloride (50.0 g, 0.118 mol) with 100 ml of methylene chloride under a nitrogen atmosphere.
- 2-(4- (piperidin-l-yl)piperidin-l-yl)acetic acid potassium salt (62.3 g, 0.236 mol) was added to 600 ml of methylene chloride. This mixture was cooled to about -10°C and stirring was continued. To this mixture isobutylchloroformate (23 ml, 0.177 mol) was added dropwise such that the temperature of the 2-(4-(piperidin-l-yl)piperidin-l-yl)acetic acid potassium salt mixture never rose appreciably.
- This reaction mixture was stirred at about -10°C for about 1.5 hours at which time the (R)-2-amino-3-(lH-indol-3-yl)-l-[N-(2- methoxybenzyl)acetylamino]propane dihydrochloride/methylene chloride mixture prepared supra was slowly added to the 2-(4-(piperidin- l-yl)piperidin-l-yl)acetic acid potassium salt isobutylchloroformate/methylene chloride solution. The resulting mixture was then stirred for about 1 hour at a temperature between - 15°C and -8°C.
- reaction mixture was removed from the ice bath and allowed to warm to 15-20°C and the reaction was quenched by the addition of 200 ml of water.
- the pH ofthe solution was adjusted to 2.3-2.7 by the additon of IN sulfuric acid.
- the layers were separated and the aqueous layer was washed with 100 ml of methylene chloride.
- the organic fractions were combined and washed with water (100 ml). The water wash was back extracted with methylene chloride (50 ml) and combined with the aqueous fraction from above. Methylene chloride (500 ml) was added to the combined aqueous layers and the mixture was stirred at room temperature for 15 minutes as basification with 2N sodium hydroxide to a final pH of 9.8 to 10.2 was achieved. The organic and aqueous fractions were separated. The aqueous fraction was washed with methylene chloride and the methylene chloride was added to the organic fraction. The organic fraction was then washed with a mixture of saturated sodium bicarbonate solution (100 ml) and water (50 ml). The bicarbonate wash was separated from the organic fraction and back extracted with methylene chloride (50 ml).
- D-tryptophan 40.0 g, 0.196 mol
- acetonitrile 240 ml
- 1,1,1,3,3,3-hexamethyldisilazane 39.5 g, 0.245 mol
- the resulting mixture was heated to 50-60°C and stirred until homogeneous.
- trityl chloride 60.06 g, 0.215 mol
- acetonitrile 120 ml
- N-trityl-D-tryptophan N-methylmopholine salt 108.0 g, 0.196 mol
- acetonitrile 800 ml
- 2-chloro-4,6-dimethoxy-l,3,5-triazine 38.63 g, 0.22 mol
- N-methylmorpholine 29.1 ml
- the resulting mixture was stirred at ambient temperature until homogeneous (about ten minutes). After about one hour, 2-methoxybenzylamine (29 ml) was added. The resulting mixture was heated to 35°C and maintained at that temperature overnight.
- RED-AL® [a 3.4 M, solution of sodium bis(2- methoxyethoxy)aluminum hydride in toluene] (535 ml, 1.819 mol), dissolved in anhydrous tetrahydrofuran (400 ml) was slowly added using an addition funnel to a refluxing solution of the acylation product, (R)-3- (lH-indol-3-yl)-N-(2-methoxybenzyl)-2-(N- triphenylmethylamino)propanamide (228.6 g, 0.404 mols) produced supra, in anhydrous tetrahydrofuran (1.0 L) under a nitrogen atmosphere. The reaction mixture became a purple solution.
- the reaction was quenched after at least 20 hours by the slow addition of excess saturated Rochelle's salt solution (potassium sodium tartrate tetrahydrate).
- the organic layer was isolated, washed with brine (2X), dried over anhydrous sodium sulfate, filtered, and concentrated to an oil on a rotary evaporator. No further purification was done and the product was used directly in the next step.
- Cyclohexylpiperazine (10.0 g, 0.059 mol) was added to ten volumes of methylene chloride at room temperature. To this mixture was added sodium hydroxide (36 ml of a 2N solution, 0.072 mol) and tetrabutylammonium bromide (1.3 g, 0.004 mol). After the addition of the sodium hydroxide and tetrabutylammonium bromide, methyl bromoacetate (7.0 ml, 0.073 mol) was added and the reaction mixture was stirred for four to six hours. The progress of the reaction was monitored by gas chromatography.
- the organic fraction was separated and the aqueous phase was back-extracted with methylene chloride.
- the organic phases were combined and washed twice with deionized water, once with saturated sodium bicarbonate solution, and then with brine.
- the organic phase was dried over magnesium sulfate and the solvents were removed in vacuo to yield methyl 2-((4-cyclohexyl)piperazin-l-yl)acetate as a yellowish oil.
- the title compound was prepared by dissolving the methyl 2-((4-cyclohexyl)piperazin-l-yl)acetate (10.0 g, 0.042 mol) in ten volumes of diethyl ether. This solution was cooled to 15°C and then potassium trimethylsilanoate (5.9 g, 0.044) was added. This mixture was then stirred for four to six hours. The reaction product was removed by filtration, washed twice with five volumes of diethyl ether, then washed twice with five volumes of hexanes, and then dried in a vacuum oven for 12-24 hours at 50°C. Analysis for C 12 H2 1 KN 2 O 2 • 1.5 H 2 O: Theory: C, 49.63; H, 7.98; N, 9.65.
- the title compound was prepared by first cooling 2-((4- cyclohexyl)piperazin-l-yl)acetic acid potassium salt to a temperature between -8°C and -15°C in 5 volumes of anhydrous methylene chloride. To this mixture was added isobutylchloroformate at a rate such that the temperature did not exceed -8°C. The resulting reaction mixture was stirred for about 1 hour, the temperature being maintained between -8°C and -15°C.
- the reaction was quenched by the addition of 5 volumes of water.
- the organic layer was washed once with a saturated sodium bicarbonate solution.
- the organic phase was then dried over anhydrous potassium carbonate and filtered to remove the drying agent.
- To the filtrate was then added 2 equivalents of concentrated hydrochloric acid, followed by 1 volume of isopropyl alcohol.
- the methylene chloride was then exchanged with isopropyl alcohol under vacuum by distillation.
- Tetrabutylammonium bromide (0.150 kg, 0.47 mol) and sodium hydroxide (1.7 L of a 5 N solution, 8.5 mol) were then added.
- the reaction mixture was cooled to 10-15°C and methyl bromoacetate (1.17 kg, 7.65 mol) was added and the resulting mixture was stirred for a minimum of 16 hours.
- Deionized water (1.2 L) was then added to the mixture and the layers separated. The aqueous layer was back-extracted with methylene chloride (2.4 L). The organic fractions were combined and washed with deionized water (3 x 1.2 L), a saturated sodium bicarbonate solution (1.1 L) and a saturated sodium chloride solution (1.1 L). The organic fraction was then dried over anhydrous magnesium sulfate and concentrated to an oil on a rotary evaporator to yield 1.613 kg (93.5%) of methyl 2-(4-(piperidin-l-yl)piperidin-l-yl)acetate.
- reaction mixture was then cooled to -35°C and solid (R)- 2-amino-3-(lH-indol-3-yl)-l-[N-(2-methoxybenzyl)amino]propane dihydrochloride (0.60 kg, 1.14 mol) was added at such a rate that the reaction temperature was maintained at less than -20°C.
- the reaction mixture was stirred for about one hour with the temperature being maintained between -37°C and -20°C.
- the reaction was quenched by the addition of deionized water (7.5 L).
- the reaction mixture was basified to pH 12.8-13.2 by the addition of 5 N sodium hydroxide.
- the aqueous fraction was removed and retained. Additional deionized water (3.75 L) was added to the organic fraction as was sufficient 5 N sodium hydroxide to re-adjust the pH to 12.8-13.2.
- the two aqueous fractions were combined, back-extracted with methylene chloride (1.5 L) and then discarded.
- the organic fractions were combined and washed with deionized water (4 x 3.5 L). These extracts were combined, back-extracted with methylene chloride (1.5 L), and then discarded.
- the two organic layers were combined and washed with a saturated sodium chloride solution (3.7 L).
- the organic fraction was dried over anhydrous magnesium sulfate, filtered, and solvent exchanged from methylene chloride to acetone (3.75 L) on a rotary evaporator.
- the mixed anhydride process will work in a number of organic solvents, in addition to the anhydrous N,N-dimethylformamide depicted above.
- solvents which may be employed include acetonitrile, tetrahydrofuran, dichloromethane.
- the mixed anhydride process can be performed at temperatures below 0°C.
- the oxalate can be isolated from ethyl acetate as well as from other solvents, probably including acetone, acetonitrile, and i-butyl methyl ether.
- the use of oxalic acid is, however, very important for the precipitation as a large number of acids do not give a precipitate.
- acids attempted, but found not satisfactory for the processes of the present invention are citric, anhydrous hydrochloric, tartaric, mandelic, trifluoroacetic, p-nitrobenzoic, phenoxyacetic, maleic, fumaric, glutaric, adipic, methanesulfonic, p-toluenesulfonic, pamoic, trans-l,2-cyclohexane dicarboxylic, succinic, phthalic, trans- l,2-diaminocyclohexane-N,N,N',N'-naphthalenedisulfonic, and 5- sulfosalicylic acids. Only oxalic acid and 1,5-naphthalene disulfonic acid reproducibly produced a solid.
- the phases were separated and the organic phase was back extracted with water (101.44 ml).
- the organic fraction was transferred to a jacketed round bottom flask and a solvent exchange was performed using about 23 volumes of acetone. Portions of the acetone were added to the product solution and the amount added was distilled away. The progress of the solvent exchange was monitored by NMR. The amount of desired product was monitored by high performance liquid chromatography. Enough water was added to bring the water concentration to eleven percent and the resulting mixture was heated to 55°C. Enough concentrated hydrochloric acid was added to lower the pH to 2.0 and the reaction mixture was then permitted to cool to 37°C over 45 minutes. The product solution was seeded and permitted to stir for 10-30 minutes.
- the product solution was cooled to 19°C over two hours and acetone (ten equivalent volumes) was added over three hours, after which time the reaction mixture was stirred for one to three hours, maintaining the temperature at 19°C.
- the product solution was filtered and the residue was washed with 6.67 equivalents of acetone. The residue was then dried in a vacuum oven at 42 °C to give the desired title product.
- the biological efficacy of a compound believed to be effective as a tachykinin receptor antagonist may be confirmed by employing an initial screening assay which rapidly and accurately measured the binding of the tested compound to known NK-1 and NK-2 receptor sites.
- Radioreceptor binding assays were performed using a derivative of a previously published protocol. D.G. Payan, et al.. Journal of Immunology. 133:3260-3265 (1984). In this assay an aliquot of IM9 cells (1 x 10 6 cells/tube in RPMI 1604 medium supplemented with 10% fetal calf serum) was incubated with 20 pM 125 I-labeled substance P in the presence of increasing competitor concentrations for 45 minutes at 4°C.
- the IM9 cell line is a well-characterized cell line which is readily available to the public. See, e.g.. Annals of the New York Academy of Sri ⁇ nce.
- reaction was terminated by filtration through a glass fiber filter harvesting system using filters previously soaked for 20 minutes in 0.1% polyethylenimine. Specific binding of labeled substance P was determined in the presence of 20 nM unlabeled ligand.
- the CHO-hNK-2R cells a CHO-derived cell line transformed with the human NK-2 receptor, expressing about 400,000 such receptors per cell, were grown in 75 cm 2 flasks or roller bottles in minimal essential medium (alpha modification) with 10% fetal bovine serum.
- minimal essential medium alpha modification
- the gene sequence of the human NK-2 receptor is given in N.P. Gerard, et fll., Journal of Biological Chemistry. 265:20455-20462 (1990).
- CHO-hNK-2R membrane preparation was suspended in 40 ml of assay buffer containing 50 mM Tris, pH 7.4, 3 mM manganese chloride, 0.02% bovine serum albumin (BSA) and 4 ⁇ g/ml chymostatin. A 200 ⁇ l volume of the homogenate (40 ⁇ g protein) was used per sample.
- the radioactive ligand was [ 125 I]iodohistidyl-neurokinin A (New England Nuclear,
- NEX-252 2200 Ci/mmol.
- the ligand was prepared in assay buffer at 20 nCi per 100 ⁇ l; the final concentration in the assay was 20 pM.
- Non-specific binding was determined using 1 ⁇ M eledoisin.
- Ten concentrations of eledoisin from 0.1 to 1000 nM were used for a standard concentration-response curve.
- DMSO dimethylsulfoxide
- IC50 IC50 determinations.
- the order of additions for incubation was 190 or 195 ⁇ l assay buffer, 200 ⁇ l homogenate, 10 or 5 ⁇ l sample in DMSO, 100 ⁇ l radioactive ligand.
- the samples were incubated 1 hr at room temperature and then filtered on a cell harvester through filters which had been presoaked for two hours in 50 mM Tris buffer, pH 7.7, containing 0.5% BSA. The filter was washed 3 times with approximately 3 ml of cold 50 mM Tris buffer, pH 7.7.
- the filter circles were then punched into 12 x 75 rnrn polystyrene tubes and counted in a gamma counter.
- the compounds of Formula I are useful in treating sleep apnea.
- the effectiveness of a compound employed in the present invention may be demonstrated using standard techniques.
- the patients who have been diagnosed with sleep apnea are given soft capsules, each containing 10 mg of (R)-3-(lH-indol-3-yl)-l-[N- (2-methoxybenzyl)acetylamino]-2-[N-(2-(4-(piperidin-l-yl)piperidin-l- yl)acetyl)amino]propane dihydrochloride trihydrate at a dose of one capsule after supper for period of days. Clinical symptoms of the patients are observed, and apnea index (times/hour) are also measured before and after administration.
- compositions comprising a pharmaceutically acceptable excipient and at least one active ingredient.
- These compositions can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal.
- Many of the compounds employed in the methods of this invention are effective as both injectable and oral compositions.
- Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. See, e.g.. REMINGTON'S PHARMACEUTICAL SCIENCES, (16th ed. 1980).
- the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container.
- a carrier which can be in the form of a capsule, sachet, paper or other container.
- the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehide, carrier or medium for the active ingredient.
- compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight ofthe active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- the active compound In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
- exdpients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acada, calrium phosphate, alginates, tragacanth, gelatin, caldum silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
- the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents.
- compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
- the compositions are preferably formulated in a unit dosage form, each dosage containing from about 0.05 to about 100 mg, more usually about 1.0 to about 30 mg, of the active ingredient.
- unit dosage form refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in assodation with a suitable pharmaceutical excipient.
- the active compounds are generally effective over a wide dosage range.
- dosages per day normally fall within the range of about 0.01 to about 30 mg/kg of body weight.
- the range of about 0.1 to about 15 mg/kg/day, in single or divided dose is esperially preferred.
- the amount of the compound actually administered will be determined by a physidan, in the light of the relevant drcumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
- dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several smaller doses for administration throughout the day.
- Hard gelatin capsules containing the following ingredients are prepared:
- the above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.
- a tablet formula is prepared using the ingredients below:
- the components are blended and compressed to form tablets, each weighing 240 mg.
- a dry powder inhaler formulation is prepared containing the following components:
- the active mixture is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.
- Tablets each containing 30 mg of active ingredient, are prepared as follows:
- Quantity Ingredient (mg/tablet)
- the active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly.
- the solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve.
- the granules so produced are dried at 50-60°C and passed through a 16 mesh U.S. sieve.
- the sodium carboxymethyl starch, magnesium stearate, and talc previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.
- Capsules each containing 40 mg of medicament are made as follows:
- Quantity Ingredient (mg/capsule)
- Suppositories each containing 25 mg of active ingredient are made as follows:
- the active ingredient(s) is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty add glycerides previously melted using the minimum heat necessary.
- the mixture is then poured into a suppository mold of nominal 2.0 g capadty and allowed to cool.
- Suspensions each containing 50 mg of medicament per 5.0 ml dose are made as follows:
- Purified water to 5.0 ml The medicament, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water.
- the sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Suffirient water is then added to produce the required volume.
- Capsules each containing 15 mg of medicament, are made as follows:
- the active ingredient(s), cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 425 mg quantities.
- An intravenous formulation may be prepared as follows:
- the white soft paraffin is heated until molten.
- the liquid paraffin and emulsifying wax are incorporated and stirred until dissolved.
- the active ingredient is added and stirring is continued until dispersed.
- the mixture is then cooled until solid.
- Sublingual or buccal tablets each containing 10 mg of active ingredient, may be prepared as follows:
- the glycerol, water, sodium citrate, polyvinyl alcohol, and polyvinylpyrrolidone are admixed together by continuous stirring and maintaining the temperature at about 90°C.
- the solution is cooled to about 50-55°C and the medicament is slowly admixed.
- the homogenous mixture is poured into forms made of an inert material to produce a drug-containing diffusion matrix having a thickness of about 2-4 mm. This diffusion matrix is then cut to form individual tablets having the appropriate size.
- transdermal delivery devices Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
- transdermal patches for the delivery of pharmaceutical agents is well known in the art. See. e.g.. U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference.
- patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
- Indirect techniques usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs or prodrugs.
- Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier.
- the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/142,028 US6001837A (en) | 1996-03-01 | 1997-02-26 | Methods of treating or preventing sleep apnea |
AU19774/97A AU1977497A (en) | 1996-03-01 | 1997-02-26 | Methods of treating or preventing sleep apnea |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1266196P | 1996-03-01 | 1996-03-01 | |
US60/012,661 | 1996-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997031633A1 true WO1997031633A1 (en) | 1997-09-04 |
Family
ID=21756079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/003028 WO1997031633A1 (en) | 1996-03-01 | 1997-02-26 | Methods of treating or preventing sleep apnea |
Country Status (3)
Country | Link |
---|---|
US (1) | US6001837A (en) |
AU (1) | AU1977497A (en) |
WO (1) | WO1997031633A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5915207A (en) * | 1996-01-22 | 1999-06-22 | Hughes Electronics Corporation | Mobile and wireless information dissemination architecture and protocols |
CA2260269A1 (en) * | 1996-07-17 | 1998-01-22 | Merck & Co., Inc. | Alteration of circadian rhythmicity with a tachykinin antagonist |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5328927A (en) * | 1992-03-03 | 1994-07-12 | Merck Sharpe & Dohme, Ltd. | Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403577B1 (en) * | 1993-11-17 | 2002-06-11 | Eli Lilly And Company | Hexamethyleneiminyl tachykinin receptor antagonists |
-
1997
- 1997-02-26 US US09/142,028 patent/US6001837A/en not_active Expired - Fee Related
- 1997-02-26 AU AU19774/97A patent/AU1977497A/en not_active Abandoned
- 1997-02-26 WO PCT/US1997/003028 patent/WO1997031633A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5328927A (en) * | 1992-03-03 | 1994-07-12 | Merck Sharpe & Dohme, Ltd. | Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
Also Published As
Publication number | Publication date |
---|---|
AU1977497A (en) | 1997-09-16 |
US6001837A (en) | 1999-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0710479B1 (en) | Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine | |
RU2140921C1 (en) | Nonpeptide antagonists of tachikinin receptors | |
AU707325B2 (en) | 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-HT4 or H3 receptor ligands | |
EP0686629A2 (en) | Cyclohexyl tachykinine receptor antagonists | |
JPH07215863A (en) | Non-peptidotachykinin receptor antagonist | |
KR100599134B1 (en) | Use of nk-1 receptor antagonists against benign prostatic hyperplasia | |
EP0699674A1 (en) | 1-Aryl-2-acetylamidopentanone derivatives for use as tachykinin receptor antagonists | |
EP0714891A1 (en) | Heterocyclic tachykinin receptor antagonists | |
CA2217461A1 (en) | 2-acylaminopropanamides as tachykinin receptor antagonists | |
JP2001503774A (en) | 5-HT lower 1F agonist | |
EP0747049A1 (en) | Use of tachykinin antagonists in combination with serotonin agonists or serotonin reuptake inhibitors for the manufacture of a medicament for the treatment of allergic rhinitis | |
EA011635B1 (en) | New heterocyclic carboxylic acid amide derivatives | |
EP0761219A1 (en) | 2-Acylaminopropanamines as growth hormone secretagogues | |
RU2282446C2 (en) | Medicinal agent for treatment of chronic articular rheumatism | |
CN115813923A (en) | Compounds for the treatment of neurogenic orthostatic hypotension | |
JP2022505849A (en) | Polymorphic compounds and their use | |
WO2017170826A1 (en) | Compound having enhancing activity for glucagon-like peptide-1 receptor actions | |
EP0747055A2 (en) | Use of tachykinin receptors antagonists for the treatment of cold and allergic rhinitis | |
US5491140A (en) | Naphthyl tachykinin receptor antagonists to treat physiological conditions | |
EP0699665B1 (en) | Imidazoline derivatives, their preparation and their use as tachykinin receptor antagonists | |
US6001837A (en) | Methods of treating or preventing sleep apnea | |
WO1997025988A1 (en) | Methods of treating or preventing pain or nociception | |
US5846973A (en) | Methods of treating pulmonary hypertension | |
US6017930A (en) | Methods of treating or preventing interstitial cystitis | |
JP2001507673A (en) | Substituted arylalkylamines as neurokinin antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09142028 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97531096 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |